Division of Pulmonary and Sleep Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Pediatr Pulmonol. 2022 Aug;57(8):1952-1962. doi: 10.1002/ppul.25512. Epub 2021 Jun 1.
Narcolepsy is a life-long sleep disorder with two distinct subtypes, narcolepsy type I and narcolepsy type II. It is now well recognized that the loss of hypocretin neurons underlies the pathogenesis of narcolepsy type I, however, the pathogenesis of narcolepsy type II is currently unknown. Both genetic and environmental factors play an important role in the pathogenesis of narcolepsy. There is increasing evidence that autoimmune processes may play a critical role in the loss of hypocretin neurons. Infections especially streptococcus and influenza have been proposed as a potential trigger for the autoimmune-mediated mechanism. Several recent studies have shown increased cases of pediatric narcolepsy following the 2009 H1N1 pandemic. The increased cases in Europe seem to be related to a specific type of H1N1 influenza vaccination (Pandemrix), while the increased cases in China are related to influenza infection. Children with narcolepsy can have an unusual presentation at disease onset including complex motor movements which may lead to delayed diagnosis. All classic narcolepsy tetrads are present in only a small proportion of children. The diagnosis of narcolepsy is confirmed by either obtaining cerebrospinal fluid hypocretin or overnight sleep study with the multiple sleep latency test (MSLT). There are limitations of using MSLT in young children such that a negative MSLT test cannot exclude narcolepsy. HLA markers have limited utility in narcolepsy, but it may be useful in young children with clinical suspicion of narcolepsy. For management, both pharmacologic and non-pharmacologic treatments are important in the management of narcolepsy. Pharmacotherapy is primarily aimed to address excessive daytime sleepiness and REM-related symptoms such as cataplexy. In addition to pharmacotherapy, routine screening of behavioral and psychosocial issues is warranted to identify patients who would benefit from bio-behavior intervention.
发作性睡病是一种终身性睡眠障碍,具有两种不同的亚型,即发作性睡病 I 型和发作性睡病 II 型。目前已经明确,发作性睡病 I 型的发病机制是下丘脑分泌素神经元缺失,而发作性睡病 II 型的发病机制目前尚不清楚。遗传和环境因素都在发作性睡病的发病机制中发挥着重要作用。越来越多的证据表明,自身免疫过程可能在下丘脑分泌素神经元缺失中发挥关键作用。感染,特别是链球菌和流感,被认为是自身免疫介导机制的潜在触发因素。最近的几项研究表明,2009 年 H1N1 大流行后,儿童发作性睡病的病例有所增加。欧洲增加的病例似乎与特定类型的 H1N1 流感疫苗(Pandemrix)有关,而中国增加的病例则与流感感染有关。发作性睡病患儿在疾病发作时可能会出现异常表现,包括复杂的运动性发作,这可能导致诊断延迟。只有一小部分儿童存在所有典型的发作性睡病四联症。发作性睡病的诊断通过获得脑脊液下丘脑分泌素或进行多导睡眠图睡眠潜伏期试验(MSLT)的整夜睡眠研究来确认。在幼儿中使用 MSLT 存在局限性,因此阴性 MSLT 测试不能排除发作性睡病。HLA 标志物在发作性睡病中的应用有限,但对于有发作性睡病临床怀疑的幼儿可能有用。对于管理,药物和非药物治疗在发作性睡病的管理中都很重要。药物治疗主要针对治疗日间过度嗜睡和 REM 相关症状,如猝倒。除了药物治疗外,还需要常规筛查行为和心理社会问题,以确定需要生物行为干预的患者。